Two years af­ter PhII set­back, Jounce's lead I/O drug flops again de­spite bio­mark­er ap­proach

When Jounce Ther­a­peu­tics’ lead drug, vo­prate­limab, failed to clear the hur­dle in a Phase II tri­al for non-small cell lung can­cer, ex­ecs pinned their hopes on a sec­ond tri­al fo­cused on a small­er group of bio­mark­er-se­lect­ed pa­tients.

Al­most two years lat­er, the biotech said that doesn’t seem to work, ei­ther.

Co-found­ed by Jim Al­li­son, who won the No­bel Prize for his work on check­point in­hibitors, Jounce has been look­ing for new ways to un­leash the im­mune sys­tem against can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER